Frankfurt / Wesel, April 26, 2007.

ALTANA seeks delisting in the U.S.

ALTANA’s Management Board has decided to delist from the New York Stock Exchange (NYSE) and to file a deregistration application with the Securities and Exchange Commission (SEC). After successful deregistration, ALTANA will no longer be subject to the regulations of the U.S. securities laws including the reporting obligations and regulations of the Sarbanes-Oxley Act resulting from a registration with the SEC. ALTANA has not arranged for the listing of its ADSs or ordinary shares on another national securities exchange or for the quotation of its common stock in a quotation medium in the United States.


The U.S. activities of ALTANA Pharma, which was sold to Nycomed as of December 31, 2006, had caused ALTANA to opt for a listing on the New York Stock Exchange in 2002. After the sale of ALTANA Pharma, this reason is no longer valid. By delisting from the NYSE, ALTANA is taking into consideration the new Group structure as a pure specialty chemicals company.



This press release contains forward-looking statements, i.e. current estimates or expectations of future events or future results. These statements are based on beliefs of ALTANA’s management as well as assumptions made by and information currently available to ALTANA. Forward-looking statements speak only as of the date they are made. ALTANA does not intend, and does not assume any obligation, to update forward-looking statements to reflect facts, circumstances or events that have occurred or changed after such statements have been made.